Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped down before the market opened on Monday . The stock had previously closed at $23.34, but opened at $22.05. Ascentage Pharma Group International shares last traded at $22.2720, with a volume of 527 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AAPG. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price target on the stock. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $46.67.

Ascentage Pharma Group International Price Performance

The firm has a 50 day moving average price of $24.19 and a 200 day moving average price of $27.31. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million during the quarter. On average, equities research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently modified their holdings of AAPG. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth $96,000. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International during the third quarter valued at about $204,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International during the third quarter valued at about $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International during the second quarter valued at about $391,000. Finally, XY Capital Ltd grew its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.